Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives

Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives

Prashanth Rawla,1 Tagore Sunkara,2 Jeffrey Pradeep Raj3 1Department of Internal Medicine, Memorial Hospital of Martinsville and Henry County, Martinsville, VA, 2Division of Gastroenterology and Hepatology, The Brooklyn Hospital Center, Clinical Affiliate of The Mount Sinai Hospital, New York, NY, US...

Full description

Bibliographic Details
Main Authors: Rawla P, Sunkara T, Raj JP
Format: Article
Language:English
Published: Dove Medical Press 2018-05-01
Series:Journal of Inflammation Research
Subjects:
Inflammatory Bowel Disease
Crohn's Disease
Ulcerative Colitis
Biologics
Biosimilars
Tumor Necrosis Factor
Integrin
Interleukin
Adalimumab
Humira
Certolizumab
Cimzia
Golimumab
Simponi
Infliximab
Remicade
Vedolizumab
Entyvio
Natalizumab
Tysabri
Ustekinumab
Stelara.
Online Access:https://www.dovepress.com/role-of-biologics-and-biosimilars-in-inflammatory-bowel-disease-curren-peer-reviewed-article-JIR

Internet

https://www.dovepress.com/role-of-biologics-and-biosimilars-in-inflammatory-bowel-disease-curren-peer-reviewed-article-JIR

Similar Items